GlassScriptPhysician profile
Danna Yang
NPI 1558963892
$16,630.74
in general payments reported to CMS, 2019-2025
22 companies · $4,470 in 2025
The $4,470 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $492 · 2022: $1,004 · 2023: $4,527 · 2024: $6,138 · 2025: $4,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,782.54 |
| Education | $351.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,378.79 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $1,947.66 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $1,724.09 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $1,694.22 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,512.08 | 2021-2025 | |
| Incyte Corporation | $1,489.87 | 2023-2025 | Opzelura |
| Janssen Biotech, INC. | $877.47 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $866.77 | 2022-2025 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $852.96 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $777.46 | 2023-2025 | |
| Almirall LLC | $729.79 | 2023-2025 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $542.99 | 2023-2024 | Vtama |
| Ucb, INC. | $453.23 | 2023-2025 | Bimzelx |
| Leo Pharma INC. | $231.27 | 2023-2025 | Adbry, Anzupgo |
| Pfizer INC. | $199.11 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Galderma Laboratories, L.P. | $61.26 | 2023-2024 | Aklief, Epsolay |
| Journey Medical Corporation | $55.70 | 2025 | |
| Organon LLC | $54.08 | 2025 | Vtama |
| Biofrontera INC. | $45.98 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.07 | 2024 | Spevigo |
| Phadia US INC. | $21.90 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danna Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.